“I would gladly test our vaccine head-to-head against any out there. It is always difficult to compare preclinical results, however, I believe our results compare extremely favorably to preclinical results reported by other companies,” Eric Marcusson, company co-founder.

Canada’s mRNA vaccine company, Providence Therapeutics, reported Wednesday that the company could deliver five million doses of its new COVID-19 vaccine by mid-2021 for use in Canada, if Ottawa would provide funding to conduct human trials to know whether it has found a possible cure for the pandemic.

Providence Therapeutics has requested $35-million from the federal government to start human trials for its COVID-19 Vaccine Candidate (PTX-COVID19-B). If the human trials are successful, a new vaccine could be made available to five million Canadians by mid-2021.

The potential vaccine when tested on mice, according to Eric Marcusson co-founder of the business, effectively blocked the entry of the novel coronavirus into the animal cells.

The Providence Therapeutics findings have yet to be peer-reviewed.

Source and more information: www.providencetherapeutics.com.